SCY-078 + Fluconazole + Echinocandin
Phase 3Terminated 0 views this week 0 watching💤 Quiet
Interest: 22/100
22
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Candidiasis, Invasive
Conditions
Candidiasis, Invasive, Candidemia
Trial Timeline
Aug 3, 2022 → Dec 16, 2025
NCT ID
NCT05178862About SCY-078 + Fluconazole + Echinocandin
SCY-078 + Fluconazole + Echinocandin is a phase 3 stage product being developed by Scynexis for Candidiasis, Invasive. The current trial status is terminated. This product is registered under clinical trial identifier NCT05178862. Target conditions include Candidiasis, Invasive, Candidemia.
What happened to similar drugs?
5 of 20 similar drugs in Candidiasis, Invasive were approved
Approved (5) Terminated (4) Active (12)
Hype Score Breakdown
Clinical
17
Activity
0
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05178862 | Phase 3 | Terminated |
Competing Products
20 competing products in Candidiasis, Invasive
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Micafungin | Astellas Pharma | Phase 1 | 29 |
| Isavuconazole + Caspofungin + Voriconazole | Astellas Pharma | Phase 3 | 40 |
| Micafungin + fluconazole | Astellas Pharma | Phase 3 | 40 |
| Micafungin (Mycamine) | Astellas Pharma | Phase 1 | 29 |
| Fluconazole + Micafungin | Astellas Pharma | Approved | 35 |
| Micafungin + Caspofungin | Astellas Pharma | Phase 3 | 40 |
| Micafungin + Fluconazole | Astellas Pharma | Phase 3 | 40 |
| Micafungin | Astellas Pharma | Phase 2 | 35 |
| micafungin + caspofungin | Astellas Pharma | Phase 3 | 40 |
| micafungin + amphotericin B deoxycholate | Astellas Pharma | Phase 3 | 32 |
| FK463 | Astellas Pharma | Phase 2 | 35 |
| Micafungin + Liposomal Amphotericin B | Astellas Pharma | Phase 3 | 40 |
| SHR8008 + Fluconazole | Jiangsu Hengrui Medicine | Phase 3 | 36 |
| SHR8008 capsule + Fluconazole capsule | Jiangsu Hengrui Medicine | Phase 3 | 36 |
| L-743,872 | Merck | Pre-clinical | 26 |
| Caspofungin | Merck | Phase 2 | 35 |
| L-743,872 | Merck | Phase 2 | 27 |
| Caspofungin + Amphotericin B Deoxycholate | Merck | Phase 2 | 27 |
| Caspofungin acetate + Placebo | Merck | Phase 2 | 27 |
| Caspofungin + Normal Saline | Merck | Approved | 43 |